Description
Product Overview / 商品概要
Hyaluronate Na Intra Articular Injection Syringe 25mg/2.5mL (ヒアルロン酸Na関節注25mgシリンジ「NIG」)
Generic: Purified Sodium Hyaluronate / 精製ヒアルロン酸ナトリウム
Therapeutic Category: Joint Function Improving Agent / 関節機能改善剤
Manufactured by: Nichi-Iko Gifu Plant Co., Ltd. / 日医工岐阜工場株式会社
Composition & Specification / 組成・規格
Active Ingredient: Purified Sodium Hyaluronate 25mg per 1 syringe (2.5mL) / 1シリンジ(2.5mL)中:精製ヒアルロン酸ナトリウム 25mg
Additives: Anhydrous sodium dihydrogen phosphate, Sodium hydrogen phosphate hydrate, Tonicity agent / 無水リン酸二水素ナトリウム、リン酸水素ナトリウム水和物、等張化剤
Appearance: Colorless, clear, viscous aqueous injection; pH 6.8–7.8; Osmolarity ratio 1.0–1.2 (relative to physiological saline)
外観: 無色澄明、粘稠な水性注射液;pH 6.8~7.8;浸透圧比 1.0~1.2(生理食塩液に対する比)
Indications / 効能効果
EN: Osteoarthritis of the knee, Periarthritis of the shoulder joint
Knee joint pain in rheumatoid arthritis (only when all of the following criteria (1)–(4) are met):
(1) Knee joint pain persists despite systemic disease control with antirheumatic drugs or other treatments
(2) Systemic inflammatory symptoms with CRP value of 10 mg/dL or less
(3) Knee joint symptoms are mild to moderate
(4) Larsen X-ray classification of the knee joint is Grade I to Grade III
JA: 変形性膝関節症、肩関節周囲炎
関節リウマチにおける膝関節痛(下記(1)~(4)の基準を全て満たす場合に限る)
(1)抗リウマチ薬等による治療で全身の病勢がコントロールできていても膝関節痛のある場合
(2)全身の炎症症状がCRP値として10mg/dL以下の場合
(3)膝関節の症状が軽症から中等症の場合
(4)膝関節のLarsen X線分類がGradeⅠからGradeⅢの場合
Dosage and Administration / 用法用量
EN:
Usually, 1 syringe per dose is administered intra-articularly into the knee joint cavity or shoulder joint (glenohumeral joint cavity, subacromial bursa, or tendon sheath of the long head of the biceps brachii) once weekly for 5 consecutive weeks in adults. The number of administrations may be adjusted based on symptoms.
Usually, 2.5 mL per dose is administered intra-articularly into the knee joint cavity once weekly for 5 consecutive weeks in adults.
As this product is administered intra-articularly, strict aseptic technique must be observed.
JA: 〈変形性膝関節症、肩関節周囲炎〉
通常、成人1回1シリンジを1週間ごとに連続5回膝関節腔内又は肩関節(肩関節腔、肩峰下滑液包又は上腕二頭筋長頭腱腱鞘)内に投与するが、症状により投与回数を適宜増減する。
〈関節リウマチにおける膝関節痛〉
通常、成人1回2.5mLを1週間毎に連続5回膝関節腔内に投与する。
本剤は関節内に投与するので、厳重な無菌的操作のもとに行うこと。
Contraindications / 禁忌
EN: Patients with a history of hypersensitivity to any component of this product
JA: 本剤の成分に対し過敏症の既往歴のある患者
Regulatory Information / 規制情報
Approval No.: 22500AMX00464
Sales Started: July 1996 / 1996年7月
Classification Code: 873999
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年
Packaging / 包装
Main Package (for sale): 2.5mL x 10 syringes / 2.5mL×10シリンジ
Other Available Packages (by special order): 2.5mL x 10 syringes
Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.




Reviews
There are no reviews yet.